Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Rhea-AI Summary
Sanuwave (NASDAQ: SNWV) reported preliminary Q1 2026 revenue of $9.6–$9.7 million, a 3–4% increase versus Q1 2025 and in line with prior guidance. Management said several good-sized deals slipped out of the quarter, and Q1 results are preliminary pending quarter-end close.
CEO noted strong practitioner interest at the SAWC conference and emphasized continued focus on Ultramist amid reimbursement headwinds.
Positive
- Preliminary revenue of $9.6–$9.7M for Q1 2026
- Revenue +3–4% YoY versus Q1 2025
- Results within prior guidance range
- High practitioner interest reported at SAWC conference
Negative
- Several good-sized deals slid out of Q1
- Reimbursement changes caused market participants to pause activity
- Q1 figures are preliminary and may be adjusted after close
News Market Reaction – SNWV
In the Apr 17 session, SNWV gained 14.37%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.5% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Q4/FY25 results | Positive | -1.3% | Record Q4 and 2025 revenues with strong margins and growth guidance. |
| Jan 09 | Prelim Q4 2025 | Positive | +1.2% | Preliminary record Q4 and full-year revenue with 29–36% growth. |
| Nov 07 | Q3 2025 results | Positive | +17.7% | Record Q3 revenue, strong margins, and raised outlook for 2025. |
| Oct 06 | Prelim Q3 2025 | Negative | -21.6% | Preliminary Q3 missed guidance and annual revenue guidance cut. |
| Aug 08 | Q2 2025 results | Positive | +15.8% | Record Q2 revenue, margin expansion, and strong UltraMIST growth. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related news has mostly produced aligned reactions, with four aligned moves and one divergence where strong results were sold off.
Over the past few quarters, Sanuwave has repeatedly highlighted record revenues and strong growth, with Q2, Q3, and Q4 2025 all marking new highs and solid profitability metrics. Guidance has generally called for continued revenue expansion, though Q3 2025 included a guidance cut tied to reimbursement uncertainty. The current Q1 2026 preliminary revenue range of $9.6–$9.7M, up 3–4% year-over-year and in line with prior guidance, follows this pattern of regular earnings updates while acknowledging reimbursement-driven volatility in the wound care market.
Key Terms
allografts medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Sanuwave is pleased to announce preliminary revenues of
EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of
“At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in toward the lower end of our guidance range,” said CEO Morgan Frank. “Q1 has been a sort of reckoning in the wound care space as practitioners and customers came to terms with some significant changes in reimbursement for skin substitutes and allografts and this has caused many market participants and practitioners to pause or pull back from their activities in advanced wound care. But, as we discussed on our Q4 call, the patients and the wounds have not gone away and the need for care remains. At the SAWC conference in Charlotte last week, we spoke to a great many practitioners who were asking ‘So what now?’ and looking for options going forward. Our booth was as busy as any of us can ever recall seeing it, our hands-on workshops were full, and interest was high. For these reasons, we’re not pulling back but rather leaning in as we believe that Ultramist can be an important part of the forward roadmap for patient care. I’m not sure we can quite say ‘the tide has fully turned’ at this point, but, at the very least, it does seem like perhaps the turn is starting and our optimism is increasing. We look forward to speaking with you further on this and providing some more color when we report our Q1 number in May.”
The preliminary revenue results described herein are based on management’s initial analysis of the first quarter ended March 31, 2026, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
